Signatur Biosciences
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Signatur Biosciences - overview
Established
2022
Location
London, -, UK
Primary Industry
Healthcare Specialists
About
Based in London, UK, and founded in 2022 by CEO Celestin of Wergifosse, Signatur Biosciences is a diagnostics company that provides breast cancer testing for local labs. In January 2025, Signatur Biosciences raised venture funding from Riceberg Ventures. Signatur Biosciences specializes in developing advanced PCR testing solutions designed to improve diagnosis for various diseases. The company’s product offerings include smart PCR kits capable of detecting gene expression signatures, making the diagnostic process as straightforward as current COVID-19 tests while leveraging standard quantitative PCR (qPCR) machines.
It enables the simultaneous analysis of multiple biomarkers through its PCRchitectur technology to support medical applications, particularly in underserved disease areas.
Current Investors
Riceberg Ventures
Primary Industry
Healthcare Specialists
Sub Industries
Diagnostic, Medical & Imaging Laboratories, Oncology/Cancer Treatment
Website
www.signatur.bio
Company Stage
Early Stage
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.